January 11, 2016

Protagonist Therapeutics, a spin-out company from IMB, has begun clinical trials with a novel drug candidate being investigated as a potential 'oral targeted therapy' for inflammatory bowel diseases.

Read more on the Protagonist Therapeutics media release.

 

 

 

On this site

Go to top